| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 144, 1357-1368, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
A Vakeva, BP Morgan, I Tikkanen, K Helin, P Laurila and S Meri
Department of Bacteriology and Immunology, University of Helsinki, Finland.
Activation of the complement (C) system has been documented in both experimental and clinical studies of myocardial infarction, but the exact time course and mechanisms leading to C activation have remained unclear. Our earlier postmortem study on human beings showed that formation of the membrane attack complex (MAC) of C was associated with loss of CD59 (protectin), an important sarcolemmal regulator of MAC, from the infarcted area. The recent discovery of a rat analogue of CD59 has now allowed the first experimental evaluation of the temporal and spatial relationship between C component deposition and loss of CD59 in acute myocardial infarction (AMI). After ligating the left coronary artery in rats the earliest sign of C activation, focal deposition of C3, was observed at 2 hours. Deposition of the early (C1, C3) and late pathway (C8, C9) components in the AMI lesions occurred at 3 hours. Glycophosphoinositol-anchored rat CD59 was expressed in the sarcolemmal membranes of normal cardiomyocytes. In Western blot analysis extracts of normal rat heart CD59 appeared as a band of 21 kd of molecular weight under nonreducing conditions. Loss of CD59 in the AMI lesions was observed in association with deposits of MAC from day one onward. Our results show that C activation universally accompanies AMI in vivo. It is initiated within 2 hours after coronary artery obstruction via deposition of C3, which may be due to generation of the alternative pathway C3 convertase in the ischemic area. Deposition of C1 and late C components also starts during the early hours (2 to 4 hours) after ischemia. Subsequent loss of the protective CD59 antigen may initiate postinjury clearance of the irreversibly damaged tissue.
This article has been cited by other articles:
 |
|
 |
|
  K. L. Hamilton, L. Lin, Y. Wang, and A. A. Knowlton Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression Physiol Genomics, January 17, 2008; 32(2): 254 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Lazar, T. Keilani, C. A. Fitzgerald, O. M. Shapira, C. T. Hunter, R. J. Shemin, H. C. Marsh Jr, U. S. Ryan, and the TP10 Cardiac Surgery Study Group Beneficial Effects of Complement Inhibition With Soluble Complement Receptor 1 (TP10) During Cardiac Surgery: Is There a Gender Difference? Circulation, September 11, 2007; 116(11_suppl): I-83 - I-88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Thurman, A. M. Lenderink, P. A. Royer, K. E. Coleman, J. Zhou, J. D. Lambris, R. A. Nemenoff, R. J. Quigg, and V. M. Holers C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion J. Immunol., February 1, 2007; 178(3): 1819 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The APEX AMI Investigators Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, January 3, 2007; 297(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vinten-Johansen Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury Cardiovasc Res, February 15, 2004; 61(3): 481 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger, K. W. Mahaffey, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, S. Rollins, T. G. Todaro, J. C. Nicolau, W. Ruzyllo, et al. Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial Circulation, September 9, 2003; 108(10): 1184 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Sohn, H. J. Kaplan, H.-J. Suk, P. S. Bora, and N. S. Bora Chronic Low Level Complement Activation within the Eye Is Controlled by Intraocular Complement Regulatory Proteins Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3492 - 3502. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Frenette, B. Cai, and J. G. Tidball Complement Activation Promotes Muscle Inflammation during Modified Muscle Use Am. J. Pathol., June 1, 2000; 156(6): 2103 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Griselli, J. Herbert, W.L. Hutchinson, K.M. Taylor, M. Sohail, T. Krausz, and M.B. Pepys C-reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction J. Exp. Med., December 20, 1999; 190(12): 1733 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mevorach, J. O. Mascarenhas, D. Gershov, and K. B. Elkon Complement-dependent Clearance of Apoptotic Cells by Human Macrophages J. Exp. Med., December 21, 1998; 188(12): 2313 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Human Heart Generates Complement Proteins That Are Upregulated and Activated After Myocardial Infarction Circ. Res., October 19, 1998; 83(8): 860 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sonntag, M. H Wagner, E. Strauss, and M. Obladen Complement and contact activation in term neonates after fetal acidosis Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1998; 78(2): 125F - 128. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. R. Weiser, T. T. V. Pechet, J. P. Williams, M. Ma, P. S. Frenette, F. D. Moore, L. Kobzik, R. O. Hines, D. D. Wagner, M. C. Carroll, et al. Experimental murine acid aspiration injury is mediated by neutrophils and the alternative complement pathway J Appl Physiol, October 1, 1997; 83(4): 1090 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Collard, A. Vakeva, C. Bukusoglu, G. Zund, C. J. Sperati, S. P. Colgan, and G. L. Stahl Reoxygenation of Hypoxic Human Umbilical Vein Endothelial Cells Activates the Classic Complement Pathway Circulation, July 1, 1997; 96(1): 326 - 333. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
